Emicizumab 150mg/1ml solution for injection vials
NHS hospitals in England used £136,995,816 of indicative cost of Emicizumab 150mg/1ml solution for injection vials in the 12 months to April 2026, about 0.5% of all hospital medicines spend. That is up 21.9% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Emicizumab 150mg/1ml solution for injection vials: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to April 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Emicizumab 150mg/1ml solution for injection vials most
By indicative cost over the 12 months to April 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| Guy's & St Thomas' Nhs Foundation Trust | £23,416,334 |
| Manchester University Nhs Ft | £23,126,498 |
| Leeds Teaching Hpls Nhs Trust | £12,088,577 |
| Oxford University Hospitals Nhs Ft | £11,520,981 |
| Univ Hpls Bristol Nhs Foundation Trust | £11,013,768 |
| Sheffield Teaching Hospitals Nhs Trust | £10,820,544 |
| Nottingham University Hospitals Trust | £9,057,375 |
| East Kent Hospitals University Nhs Ft | £5,337,813 |
| Barts Health Nhs Trust | £5,301,584 |
| Royal Free London Nhs Foundation Trust | £4,323,387 |
The primary-care picture
No confident match to a community-dispensed medicine was found for this product, so no primary-care comparison is shown. SCMD products are recorded at product level, which does not always map cleanly to a BNF substance.